The present invention is based on the elucidation of the global changes in gene expression and the identification of toxicity markers in tissues or cells exposed to a known renal toxin. The genes may be used as toxicity markers in drug screening and toxicity assays. The invention includes a database of genes characterized by toxin-induced differential expression that is designed for use with microarrays and other solid-phase probes.
Legal claims defining the scope of protection, as filed with the USPTO.
1. A method for determining whether a test compound is a renal toxin, comprising: (a) exposing kidney tissue or kidney cells to the test compound; (b) preparing a normalized gene expression profile of at least ten genes for said kidney tissue or kidney cells, wherein the gene expression profile contains the differential gene expression values for said at least ten genes upon exposure to the test compound, and wherein said at least ten genes correspond to sequences listed in one of Tables 5-5CC; (c) comparing the gene expression profile to a renal toxicity model, the renal toxicity model comprising information from one or more of Tables 5-5CC, and comprising: (i) the normalized mean expression levels of said at least ten genes in kidney tissue or kidney cells exposed to a known renal toxin, and (ii) the normalized mean expression levels of said at least ten genes in unexposed kidney tissue or kidney cells; and (d) scoring the comparison to determine whether the test compound is a renal toxin.
2. The method of claim 1 , wherein the gene expression profile comprises the differential gene expression values for at least 100 genes that correspond to sequences listed in Table 5, and wherein the renal toxicity model comprises the Tox Mean and Nontox Mean gene expression values in Tables 5-5CC.
3. The method of claim 1 , wherein said gene expression profile is generated by hybridization of nucleic acids to a microarray, and is normalized for hybridization conditions, label intensity, and reading efficiency prior to comparison.
4. The method of claim 1 , wherein the renal toxicity model comprises all the information in any one of Tables 5-5CC.
5. The method of claim 1 , wherein the kidney tissue or kidney cells are exposed to the test compound in vivo and the renal toxicity model is generated by exposure of kidney tissue or kidney cells to the known renal toxin in vivo.
6. The method of claim 1 , wherein the known renal toxin is associated with at least one of nephritis, kidney necrosis, glomerular or tubular injury, and focal segmental glomerulosclerosis.
7. The method of claim 1 , wherein the known renal toxin is one or more of cephaloridine, cisplatin, puromycin aminonucleoside (PAN), bromoethylamine hydrobromide (BEA), gentamicin, ifosfamide, cyclophosphamide, carboplatin, AY-25329, indomethacin, acyclovir, citrinin, mercuric chloride, diflunisal, cidofovir, pamidronate, lithium chloride, hydralazine, coichicine, sulfadiazine, and adriamycin.
8. The method of claim 1 , wherein the kidney tissue or kidney cells exposed to the test compound are rat kidney tissue or rat kidney cells, and the renal toxicity model is generated by exposure of rat kidney tissue or rat kidney cells to the known renal toxin.
9. The method of claim 1 , wherein the gene expression profile contains the differential gene expression values for at least 20 genes that correspond to sequences listed in Table 5.
10. The method of claim 1 , wherein the gene expression profile contains the differential gene expression values for at least 30 genes that correspond to sequences listed in Table 5.
11. The method of claim 1 , wherein the known renal toxin is associated with nephrogenic diabetes insipidus.
Cooperative Patent Classification codes for this invention. Click any code to explore related patents in that topic.
May 22, 2002
August 19, 2008
Browse 5M+ US patents with plain-English claim translations and AI-generated analysis.